Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates
NCT07689149Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Primary completion
- Dec 2029
01
Overview
A Phase 4 trial of blinatumomab, teclistamab in end stage renal disease (ESRD), Human Leukocyte Antigen Sensitization, sponsored by West China Hospital of Sichuan University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
blinatumomabteclistamab
03
Conditions
end stage renal disease (ESRD)Human Leukocyte Antigen Sensitization
Beyond the preview
Go deeper on NCT07689149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689149.